Computational/in silico methods in drug target and lead prediction

FE Agamah, GK Mazandu, R Hassan… - Briefings in …, 2020 - academic.oup.com
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …
被引用次数：172 相关文章
[PDF] academia.edu

[PDF][PDF] Computational/in silico methods in drug target and lead prediction

FE Agamah, GK Mazandu, R Hassan… - Briefings in …, 2020 - academia.edu
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …

Computational/in silico methods in drug target and lead prediction

FE Agamah, GK Mazandu, R Hassan… - Briefings in …, 2020 - academic.oup.com
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …
[HTML] nih.gov

[HTML][HTML] Computational/in silico methods in drug target and lead prediction

FE Agamah, GK Mazandu, R Hassan… - Briefings in …, 2020 - ncbi.nlm.nih.gov
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …
[PDF] researchgate.net

[PDF][PDF] Computational/in silico methods in drug target and lead prediction

FE Agamah, GK Mazandu, R Hassan, CD Bope… - 2019 - researchgate.net
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …

Computational/in silico methods in drug target and lead prediction.

FE Agamah, GK Mazandu, R Hassan… - Briefings in …, 2020 - europepmc.org
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …

Computational/in silico methods in drug target and lead prediction

FE Agamah, GK Mazandu, R Hassan… - Briefings in …, 2020 - pubmed.ncbi.nlm.nih.gov
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …

Computational/in silico methods in drug target and lead prediction.

FE Agamah, GK Mazandu, R Hassan… - Briefings in …, 2020 - search.ebscohost.com
Drug-like compounds are most of the time denied approval and use owing to the
unexpected clinical side effects and cross-reactivity observed during clinical trials. These …